AmnioAMP vs Rampart: Clinical Outcomes Comparison 2026

AmnioAMP Clinical Outcomes & Rampart Comparison 2026

> Why this matters: Procurement and clinical queries for "amnioamp clinical outcomes" expect a direct answer grounded in evidence. The class-level data are encouraging, yet any product-specific claim — closure percentages, cost per square centimeter, or superiority over another branded dehydrated membrane — must be traceable to a published trial or payer document.

---

What the Clinical Evidence Shows for AmnioAMP-Class Outcomes

Because AmnioAMP-MP itself has not been studied in a stand-alone, peer-reviewed randomized trial, the safest way to discuss AmnioAMP clinical outcomes is to anchor them in the broader dehydrated human amnion/chorion membrane (dHACM) literature. These studies used products with the same general processing approach — dehydration, terminal sterilization, room-temperature storage — and report outcomes that clinicians would expect to extrapolate cautiously to AmnioAMP-MP.

Diabetic foot ulcer outcomes

- DiDomenico et al. (PMID: 30019528) reported that aseptically processed, dehydrated human amnion and chorion membrane improved the likelihood and rate of healing in chronic DFUs compared with standard care in a prospective, randomized, multicenter trial of 80 patients. - Tettelbach et al. (PMID: 30136445) confirmed that finding in a larger confirmatory study of 110 patients from 14 wound clinics, again favoring dHACM over standard care. - Cazzell et al. (PMID: 38973638) published a 2024 randomized controlled trial showing dehydrated amnion chorion membrane improved DFU healing versus standard of care. - Narayan et al. (PMID: 39649230) compared a high-purity collagen skin substitute with dehydrated human amnion/chorion membrane in a randomized DFU trial, providing the only recent comparative data point between two advanced wound products in this space.

Venous leg ulcer outcomes

- Serena et al. (PMID: 25224019) found that dehydrated human amnion/chorion membrane plus multilayer compression therapy improved VLU healing compared with compression alone in a multicenter randomized trial. - Serena et al. (PMID: 26551645) later showed that 4-week response to dHACM correlated with 24-week closure, giving clinicians an early stop/go signal. - Bianchi et al. (PMID: 29024419) reported efficacy of a dehydrated human amnion/chorion membrane allograft for VLUs in a multicenter randomized controlled trial. - Nagasaki et al. (PMID: 41802539) reported 2026 real-world outcomes and prognostic determinants for dHACM in refractory venous leg ulcers — the most recent VLU evidence in this class.

---

Key AmnioAMP-Class Outcomes at a Glance

| Outcome domain | DFU evidence | VLU evidence | Clinical implication | |---|---|---|---| | 12-week closure | dHACM improved closure vs standard care (DiDomenico PMID 30019528; Tettelbach PMID 30136445) | dHACM + compression improved healing vs compression alone (Serena PMID 25224019) | Class-supported adjunct after SOC stall; no AmnioAMP-specific RCT | | Time-to-heal | Faster healing reported in dHACM arms of RCTs | 4-week response predicts 24-week closure (Serena PMID 26551645) | Use early wound-area reduction as a continuation signal | | Amputation / limb salvage | No product-specific amputation trial identified | Not a primary endpoint in published dHACM VLU trials | Do not select or market based on unproven amputation claims | | Cost-effectiveness | Cost effectiveness depends on acquisition cost, application frequency, and total episode cost (Nherera PMID 38524772; Driver PMID 35148642; Carter PMID 38832861) | Cost-effectiveness of dHACM plus compression reported vs standard pathways (Tettelbach PMID 38457298) | Evaluate against product-specific Q-code reimbursement, not list price alone | | Real-world / registry | Medicare debridement-interval analysis reports outcomes with dHACM use in routine care (Tettelbach PMID 36240797) | Refractory VLU cohort study reports healing outcomes and prognostic determinants (Nagasaki PMID 41802539, 2026) | Real-world data complement RCTs; neither isolates one branded product |

> Important limitation: These studies evaluate dehydrated amniotic membrane as a class. They do not establish that AmnioAMP-MP produces identical outcomes, nor do they compare AmnioAMP-MP with Rampart DL Matrix. Extrapolate cautiously and disclose the absence of head-to-head branded data to patients and value analysis committees.

---

AmnioAMP vs Rampart: Product Background

Both AmnioAMP (NextGen Biologics) and Rampart DL Matrix (Rampart Medical) are dehydrated human amniotic membrane wound products stored at room temperature — neither is cryopreserved, and neither requires a freezer or cold-chain logistics. The meaningful difference between them is layer count and orientation:

- AmnioAMP is a single-layer dehydrated amniotic membrane. It is side-specific (the stromal/basement-membrane side contacts the wound bed) and is billed under HCPCS code Q4250 per square centimeter. - Rampart DL Matrix is a dual-layer dehydrated amniotic membrane. It is non-side specific (either surface can contact the wound bed, simplifying placement) and is billed under HCPCS code Q4347 per square centimeter.

Both require a brief 2–3 minute rehydration in sterile saline before application. No published head-to-head clinical trial directly compares these two branded products. The decision between them should rest on wound geometry, handling preference, payer coding, and current product labeling — not on unsupported claims of clinical superiority.

> Key Takeaway: AmnioAMP and Rampart are both room-temperature dehydrated membranes. Rampart adds a second tissue layer (more mechanical bulk, non-side-specific placement); AmnioAMP's single layer conforms more easily to irregular surfaces. Choose based on wound characteristics and workflow, and treat any specific closure-rate or cost-per-square-centimeter claim that is not sourced to a published study or payer document with skepticism.

---

Side-by-Side Comparison Table

| Feature | AmnioAMP-MP | Rampart DL Matrix | |---|---|---| | Tissue format | Dehydrated human amniotic membrane (DDHAM) | Dehydrated dual-layer human amniotic membrane | | Layer count | Single layer | Dual layer | | Storage | Room temperature | Room temperature | | Cold chain required | No | No | | Cell viability | Non-viable (matrix retained) | Non-viable (matrix retained) | | Rehydration | 2–3 min, sterile saline | 2–3 min, sterile saline | | Orientation | Side-specific (stromal side down) | Non-side specific | | HCPCS code | Q4250 (per sq cm) | Q4347 (per sq cm) | | CPT application codes | 15271–15278 | 15271–15278 | | Published head-to-head RCTs (vs. each other) | None identified | None identified |

---

Reimbursement and Billing (2026)

Amniotic membrane billing in 2026 operates under the CMS skin-substitute framework, where each product carries its own HCPCS Q-code billed per square centimeter. AmnioAMP-MP maps to Q4250; Rampart DL Matrix maps to Q4347. The CPT application codes 15271–15278 apply to the placement procedure regardless of which product is used.

Under the current CMS payment structure, reimbursement is product-specific rather than format-based — meaning a wound center's margin depends on the acquisition cost of the specific product relative to its Q-code reimbursement rate. Prior authorization requirements and coverage criteria vary by payer and Medicare Administrative Contractor (MAC). Always verify the current Local Coverage Determination (LCD), product-specific coding, and payer policy before scheduling or submitting claims. Do not assume one product's Q-code or coverage terms apply to another.

---

FAQ

AmnioAMP clinical outcomes are the wound-healing results reported in peer-reviewed studies of dehydrated human amniotic membrane allografts, the same product class that includes AmnioAMP-MP. The most cited outcomes are 12-week closure rates in diabetic foot ulcers and venous leg ulcers, time-to-heal, and wound-area reduction after standard care has stalled. The evidence supports the amniotic membrane class as an adjunct for selected chronic wounds, but no head-to-head randomized trial isolates AmnioAMP-MP from other branded products.

No PubMed-indexed randomized trial evaluates AmnioAMP-MP as the sole intervention. Published outcomes come from trials of dehydrated human amnion/chorion membrane (dHACM) products that share the same general processing approach, including studies by DiDomenico (PMID 30019528), Tettelbach (PMID 30136445), Cazzell (PMID 38973638), and Narayan (PMID 39649230) in diabetic foot ulcers, and Serena (PMID 25224019, PMID 26551645) and Bianchi (PMID 29024419) in venous leg ulcers.

Class-level randomized trials of dehydrated amniotic membrane products report improved likelihood and rate of healing in chronic diabetic foot ulcers compared with standard care. DiDomenico et al. (PMID 30019528) and Tettelbach et al. (PMID 30136445) both found dHACM superior to standard care in multicenter DFU trials. These findings apply to the product class, not uniquely to AmnioAMP-MP.

Both AmnioAMP and Rampart are dehydrated human amniotic membrane wound products stored at room temperature. The main difference is layer count: AmnioAMP is a single-layer membrane (side-specific, stromal side toward the wound bed), while Rampart DL Matrix is a dual-layer membrane that is non-side specific. AmnioAMP is billed under HCPCS Q4250; Rampart DL Matrix is billed under HCPCS Q4347. Both require 2-3 minutes of rehydration in sterile saline before application. No published head-to-head clinical trial compares these two brands directly.

Rampart DL Matrix is a dehydrated amniotic membrane product stored at room temperature. It is not cryopreserved and does not require frozen storage or cold chain logistics. This is a common point of confusion because some amniotic membrane products on the market are cryopreserved, but Rampart and AmnioAMP are both dehydrated formats.

There is no published head-to-head trial comparing AmnioAMP and Rampart specifically for venous leg ulcers. The broader class of amniotic membrane allografts has been studied as an adjunct for chronic wounds after standard care has stalled, but the evidence does not rank one of these two branded dehydrated products above the other. Selection for VLU should be based on wound characteristics, handling logistics, payer coding, and the current product label.

AmnioAMP-MP is billed under HCPCS Q4250 per square centimeter. Rampart DL Matrix is billed under HCPCS Q4347 per square centimeter. Both are product-specific Q-codes under the CMS skin-substitute billing framework. The CPT application codes 15271-15278 also apply to the application procedure. Coverage and prior-authorization requirements vary by payer and Medicare Administrative Contractor (MAC); always verify the current Local Coverage Determination (LCD) and product-specific coding before submitting claims.

No. Dehydrated amniotic membrane products like AmnioAMP and Rampart do not contain viable cells. The dehydration process removes moisture and eliminates living cells, but it preserves the structural extracellular matrix proteins (collagen, fibronectin, laminin) and the growth factors and cytokines bound to that matrix. Current research suggests that the wound-healing activity of dehydrated membranes derives from these matrix-bound signaling molecules rather than from cellular viability.

---

Clinical Takeaway

AmnioAMP and Rampart are both dehydrated, room-temperature amniotic membrane products derived from placental tissue, but they are not interchangeable: Rampart's dual-layer, non-side-specific format trades mechanical bulk and placement simplicity against AmnioAMP's single-layer conformability and different HCPCS coding. The public evidence does not support specific clinical superiority claims for either product. The strongest decision factors are regulatory clarity, payer coding, handling logistics, and local quality data — not marketing comparisons.

---

Related Resources

- Amniotic Membrane Science: A Clinician's Guide to Placental Allografts - AmnioAMP reapplication schedule & storage FAQ — cadence, visit timing, and storage/rehydration answers for clinic staff. - AmnioAMP application protocol (2026) — step-by-step application and coding. - In-office AmnioAMP-MP application technique - AmnioAMP clinical outcomes: DFU case series review - What is AmnioAMP? product overview - AmnioFix vs AmnioAMP injectable comparison — dehydrated membrane injectables compared

References

1. DiDomenico LA, et al. Use of an aseptically processed, dehydrated human amnion and chorion membrane improves likelihood and rate of healing in chronic diabetic foot ulcers. International Wound Journal. 2018. PMID: 30019528. 2. Tettelbach W, et al. A confirmatory study on the efficacy of dehydrated human amnion/chorion membrane dHACM allograft in the management of diabetic foot ulcers. International Wound Journal. 2019. PMID: 30136445. 3. Cazzell SM, et al. Dehydrated Amnion Chorion Membrane versus standard of care for diabetic foot ulcers: a randomised controlled trial. Journal of Wound Care. 2024. PMID: 38973638. 4. Narayan N, et al. A Randomized Controlled Clinical Trial Comparing the Use of High Purity Type-I Collagen-Based Skin Substitute vs. Dehydrated Human Amnion/Chorion Membrane in the Treatment of Diabetic Foot Ulcers. Cureus. 2024. PMID: 39649230. 5. Serena TE, et al. A multicenter, randomized, controlled clinical trial evaluating the use of dehydrated human amnion/chorion membrane allografts and multilayer compression therapy vs. multilayer compression therapy alone in the treatment of venous leg ulcers. Wound Repair and Regeneration. 2014. PMID: 25224019. 6. Serena TE, et al. Dehydrated human amnion/chorion membrane treatment of venous leg ulcers: correlation between 4-week and 24-week outcomes. Journal of Wound Care. 2015. PMID: 26551645. 7. Bianchi C, et al. A multicentre randomised controlled trial evaluating the efficacy of dehydrated human amnion/chorion membrane (EpiFix) allograft for the treatment of venous leg ulcers. International Wound Journal. 2018. PMID: 29024419. 8. Nherera LM, et al. Cost effectiveness of human cell and tissue products in diabetic foot ulcers. Health Science Reports. 2024. PMID: 38524772. 9. Su YN, et al. Human amniotic membrane allograft, a novel treatment for chronic diabetic foot ulcers: A systematic review and meta-analysis of randomised controlled trials. International Wound Journal. 2020. PMID: 32119765. 10. Mohammed YA, et al. Human amniotic membrane products for patients with diabetic foot ulcers: do they help? A systematic review and meta-analysis. Journal of Foot and Ankle Research. 2022. PMID: 36104736. 11. Hu X, et al. Comparison of the efficacy of 12 interventions in the treatment of diabetic foot ulcers: a network meta-analysis. PeerJ. 2025. PMID: 40821981. 12. Tettelbach W, et al. Outcomes for Medicare debridement intervals receiving dehydrated human amnion/chorion membrane. Journal of Wound Care. 2022. PMID: 36240797. 13. Nagasaki K, et al. Clinical outcomes and prognostic determinants of dehydrated human amnion/chorion membrane for refractory venous leg ulcers. Journal of Vascular Surgery: Venous and Lymphatic Disorders. 2026. PMID: 41802539. 14. Driver VR, et al. Cost-effectiveness of dehydrated human amnion/chorion membrane allografts in lower extremity diabetic ulcers. International Wound Journal. 2022. PMID: 35148642. 15. Tettelbach W, et al. Dehydrated human amnion chorion membrane to treat venous leg ulcers: a cost-effectiveness analysis. Journal of Wound Care. 2024. PMID: 38457298. 16. Carter MJ, et al. Counting the cost of cellular and/or tissue-based products in diabetic foot ulcers. Advances in Wound Care. 2025. PMID: 38832861.

---